Skip to main content
Equibles
DCTH logo

DCTH · Delcath Systems, Inc.

Track DCTH — free

Use DCTH with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about DCTH

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$16.73 -0.63 (-3.63%) At close · Aug 14
Market Cap
$580.51M
Shares
34.70M

Delcath Systems, Inc. Earnings Call Transcripts

Every quarterly earnings call for Delcath Systems, Inc. (DCTH) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $797,000 −$10.16M '22 Q2 22-06-30 · $906,000 −$8.88M '22 Q3 22-09-30 · $638,000 −$8.47M '22 Q4 23-03-27 ▲57.9% $597,000 −$9.00M '23 Q1 23-05-12 ▼52.1% $434,000 −$20.34M '23 Q3 23-11-13 ▼15.5% $539,000 −$11.14M '23 Q4 24-03-26 ▲425.8% $3.14M −$11.11M '24 Q1 24-05-14 ▲1468.9% $7.77M −$13.74M '24 Q2 24-08-05 ▲2480.6% $11.20M $1.86M '24 Q3 24-11-08 ▲2701.5% $15.10M −$3.40M '24 Q4 25-03-06 ▲530.3% $19.78M $1.07M '25 Q1 25-05-08 ▲211% $24.16M $2.70M '25 Q2 25-08-06 ▲83.6% $20.56M $830,000 '25 Q3 25-10-20 ▲37.3% $20.73M −$1.90M '25 Q4 26-02-26 ▲26.3% $24.99M −$1.07M '26 Q1 26-05-07 LATEST ▲20.6% $29.13M $2.67M '26 Q2 26-08-06
Earnings call
FY26 · Q2
2026-08-06
Delcath Systems, Inc. Q2 FY2026 Earnings Call
Confident tone Clinical pipeline in liver-dominant cancers R&D investment Treatment center activation and expansion
Revenue
$29.13M
▲ 20.6% YoY
Diluted EPS
$0.07
▲ 0% YoY
Gross margin
89.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Delcath Systems, Inc. Q1 FY2026 Earnings Call
Positive tone Metastatic colorectal cancer (CRC) Phase II trial Center activations and commercial expansion Hepzato/Kit revenue and volume growth
Revenue
$24.99M
▲ 26.3% YoY
Diluted EPS
$-0.03
▼ 200% YoY
Gross margin
85.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Delcath Systems, Inc. Q4 FY2025 Earnings Call
Confident tone Seasonality and capacity variability Referral network development CHOPIN trial data and clinical evidence
Revenue
$20.73M*
▲ 37.3% YoY
Gross margin
85.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-20
Delcath Systems, Inc. Q3 FY2025 Earnings Call
Positive tone CHOPIN trial results Financial outlook and capital Pipeline expansion (CRC, breast, NSCLC)
Revenue
$20.56M
▲ 83.6% YoY
Diluted EPS
$0.02
▼ 66.7% YoY
Gross margin
87.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Delcath Systems, Inc. Q2 FY2025 Earnings Call
Positive tone 340B / National Drug Rebate Agreement (NDRA) pricing HEPZATO commercial launch and revenue growth CHEMOSAT European sales and clinical-site leverage
Revenue
$24.16M
▲ 211% YoY
Diluted EPS
$0.07
Gross margin
86.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Delcath Systems, Inc. Q1 FY2025 Earnings Call
Confident tone Revenue growth Pipeline trials European market
Revenue
$19.78M
▲ 530.3% YoY
Diluted EPS
$0.03
Gross margin
85.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-06
Delcath Systems, Inc. Q4 FY2024 Earnings Call
Confident tone HEPZATO U.S. launch and revenue ramp Clinical trials and pipeline expansion European CHEMOSAT growth
Revenue
$15.10M*
▲ 2701.5% YoY
Gross margin
85.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-08
Delcath Systems, Inc. Q3 FY2024 Earnings Call
Confident tone Pipeline Expansion Beyond Uveal Melanoma CHEMOSAT European Sales CHOPIN and SCANDIUM 3 Trials
Revenue
$11.20M
▲ 2480.6% YoY
Diluted EPS
$0.06
Gross margin
85.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-05
Delcath Systems, Inc. Q2 FY2024 Earnings Call
Positive tone CHEMOSAT European sales HEPZATO U.S. revenue Center activation and site ramp
Revenue
$7.77M
▲ 1468.9% YoY
Diluted EPS
$-0.48
Gross margin
80.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Delcath Systems, Inc. Q1 FY2024 Earnings Call
Confident tone U.S. Commercial Launch / Center Activation Reimbursement / J-Code Oncology Referrals and Market Penetration
Revenue
$3.14M
▲ 425.8% YoY
Diluted EPS
$-0.45
Gross margin
71.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-26
Delcath Systems, Inc. Q4 FY2023 Earnings Call
Confident tone Reimbursement and coding Commercial launch of HEPZATO KIT Liver-directed therapy evidence and pipeline
Revenue
$539,000*
▼ 15.5% YoY
Gross margin
68.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-13
Delcath Systems, Inc. Q3 FY2023 Earnings Call
Revenue
$434,000
▼ 52.1% YoY
Diluted EPS
$-1.14
Gross margin
69.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-12
Delcath Systems, Inc. Q1 FY2023 Earnings Call
Revenue
$597,000
▲ 57.9% YoY
Diluted EPS
$-0.77
Gross margin
69.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-27
Delcath Systems, Inc. Q4 FY2022 Earnings Call
Revenue
$638,000*
Gross margin
62.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-09-30
Delcath Systems, Inc. Q3 FY2022 Earnings Call
Revenue
$906,000
Diluted EPS
$-0.96
Gross margin
74.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Delcath Systems, Inc. Q2 FY2022 Earnings Call
Revenue
$797,000
Diluted EPS
$-1.24
Gross margin
77.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
Delcath Systems, Inc. Q1 FY2022 Earnings Call
Revenue
$378,000
Diluted EPS
$-1.10
Gross margin
91.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-29
Delcath Systems, Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Delcath Systems, Inc. Q3 FY2021 Earnings Call
Diluted EPS
$-0.94
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-11
Delcath Systems, Inc. Q2 FY2021 Earnings Call
Diluted EPS
$-0.96
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-12
Delcath Systems, Inc. Q1 FY2021 Earnings Call
Diluted EPS
$-1.04
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
Delcath Systems, Inc. Q4 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-09-30
Delcath Systems, Inc. Q3 FY2020 Earnings Call
Diluted EPS
$-1.16
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-18
Delcath Systems, Inc. Q2 FY2020 Earnings Call
Diluted EPS
$-1.90
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–24 of 24 earnings calls
Key facts CIK 872912 CUSIP 24661P807 13F (30d) 119 filings 115 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)